Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age‐related macular degeneration patients

Purpose To investigate the difference of optical coherence tomography (OCT) findings between aflibercept treatment group and ranibizumab treatment group. Methods This study include 63 patients (n = 63 eyes) diagnosed with treatment‐naïve neovascular AMD, and they were treated with aflibercept or ranibizumab monthly for 3 months. We compared the changes of the two groups between before the treatment and after the treatment with optical coherence tomography (OCT) findings such as serous pigment epithelium detachment, fibrovascular pigment epithelium detachment, subretinal fluid, intraretinal fluid, dense zone of outer retina, classic neovascularization, and hyper‐reflective dots. And we also compared the changes of BCVA and IS/OS length, ELM length, central foveal thickness with optical OCT between the two groups. Results There were no significant differences between two groups before each treatments. Serous pigment epithelium detachments were disappeared 36% in aflibercept group, 5% in ranibizumab group, and there was significant difference between the two groups (p = 0.021). There was no significant changes such as BCVA change, OCT finding changes except for serous pigment epithelium detachment between the two groups. Conclusions For treatment of neovascular AMD patients, aflibercept might be more effective in serous pigment epithelium detachment than ranibizumab. Because there was no significant visual acuity improvement in serous pigment detachment improvement group in both two treatments, it might be necessary to study further about relationship between visual acuity and serous pigment detachment improvement.